
Sign up & start saving!
Our monthly newsletter is launching soon with the latest in money news, credit card offers + more ways to save
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Xenetic Biosciences, Inc is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around $436,942.
Latest market close | $N/A |
---|---|
52-week range | $0.76 - $3.84 |
50-day moving average | $2.3166 |
200-day moving average | $1.8969 |
Wall St. target price | $5 |
PE ratio | 0.8151 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-12.323 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Xenetic Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xenetic Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xenetic Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Xenetic Biosciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Revenue TTM | USD$436,942 |
---|---|
Gross profit TTM | USD$436,942 |
Return on assets TTM | -16.9% |
Return on equity TTM | -74.03% |
Profit margin | 0% |
Book value | $1.397 |
Market capitalisation | USD$16.4 million |
TTM: trailing 12 months
There are currently 96,873 Xenetic Biosciences shares held short by investors – that's known as Xenetic Biosciences's "short interest". This figure is 23.1% down from 125,985 last month.
There are a few different ways that this level of interest in shorting Xenetic Biosciences shares can be evaluated.
Xenetic Biosciences's "short interest ratio" (SIR) is the quantity of Xenetic Biosciences shares currently shorted divided by the average quantity of Xenetic Biosciences shares traded daily (recently around 269091.66666667). Xenetic Biosciences's SIR currently stands at 0.36. In other words for every 100,000 Xenetic Biosciences shares traded daily on the market, roughly 360 shares are currently held short.
However Xenetic Biosciences's short interest can also be evaluated against the total number of Xenetic Biosciences shares, or, against the total number of tradable Xenetic Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenetic Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Xenetic Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0121% of the tradable shares (for every 100,000 tradable Xenetic Biosciences shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xenetic Biosciences.
Find out more about how you can short Xenetic Biosciences stock.
We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Xenetic Biosciences's shares were split on a 1:12 basis on 24 June 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.
Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $0.76 up to $3.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.5262. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Companies are going public via direct listings and IPOs. Which should you invest in?
Read more…Biden’s plan to replace the federal fleet with American-made electric vehicles gives another boost to a red-hot sector led by Tesla.
Read more…Cruise ship stocks are sailing through murky waters, but can they rise?
Read more…Steps to owning and managing SNY, with 24-hour and historical pricing before you buy.
Steps to owning and managing NorthWestern Corporation stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Noble Corporation stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing NMI stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing nLIGHT stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing NIO stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Nielsen stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Newtek Business Services stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing New Fortress Energy stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing NeoGenomics stocks, with 24-hour and historical pricing before you buy.